RYE, N.Y., Dec. 13, 2010 /PRNewswire/ — Curemark, LLC,
a drug research and development company focused on the treatment of
neurological diseases, has appointed Jennifer Katritos, CPA, as
vice president of finance, the company announced. She joined
Curemark in July, 2009 as director of finance. Katritos
oversees Curemark’s financial function, responsible for financial
planning and reporting and risk analysis.
During her 20-year career, Katritos has held a variety of
financial positions, primarily in the research-focused nonprofit
sector. Prior to Curemark, she served as director of finance
for the Multiple Myeloma Research Foundation and the Multiple
Myeloma Research Consortium. Previously, Katritos headed her
own financial consulting practice with a focus on nonprofit and
“We are extremely pleased about Jennifer’s well-deserved and
well-earned promotion,” said Joan Fallon, Curemark founder and CEO.
“She came to Curemark with a stellar financial background and
extensive experience in the research space. She has exhibited
strong leadership in the financial arena.”
“It has been incredibly rewarding to utilize my financial
expertise in a way that helps individuals in need. I am
particularly thrilled to be working with Joan and the Curemark
team,” Katritos said. “I am inspired by their dedication to
help children and families with the pervasive issue of autism.”
Katritos began her career with Deloitte and Touche LLP in New
York. She holds a BS in Accounting and Finance from the State
University of New York at Oneonta.
Curemark is currently in Phase III clinical trials for CM-AT, an autism treatment
which has received Fast Track status from the FDA.
About CUREMARK LLC
Curemark is a drug research and development company focused on
the treatment of neurologi